JEFFREY T. MILLER, District Judge.
Trivitis, Inc. ("Trivitis") and Ocean Spray Cranberries, Inc. ("Ocean Spray") separately move for summary judgment pursuant to Federal Rule of Civil Procedure 56. Ocean Spray also moves to exclude the expert testimony of Drake Larson and Dale Shellhamer. All motions are opposed. Having carefully considered the matters presented, appropriate legal authorities, the court record, and for the reasons stated below, the court grants the motion to exclude the expert testimony of Drake Larson and Dale Shellhamer, grants Ocean Spray's motion for summary judgment, denies Plaintiff's motion for summary judgment, and instructs the Clerk of Court to close the file.
On February 10, 2010, Trivitis commenced this federal question action alleging a single claim for patent infringement. Trivitis is the alleged owner of the Patent entitled "Catechin Multimers as Therapeutic Drug Delivery Agents," U.S. Patent No. 6,562,864 (the "`864 Patent" or the "Patent"). (Compl. ¶8; Ocean Spray Exh. A). Trivitis alleges that Ocean Spray is infringing its patent rights by making, using, offering to sell or selling "products that practice inventions claimed in the `864 Patent, including but not limited to, its CRANERGY Energy Juice Drink." (Compl. ¶10).
Ocean Spray produces a drink called Cranergy that allegedly infringes claims 10 and 11 of the `864 patent. (Compl. ¶10; Trivitis Brief at p.2:3-9). Cranergy is a cranberry juice drink "enhanced with natural caffeine from green tea extract and added B Vitamins."
On August 18, 2011 the court issued an order construing five disputed terms of the `864 Patent. The court adopted the following constructions.
In its infringement contentions, Trivitis alleges that Cranergy's green tea extract contains epigallocatechin gallate, the "catechin multimer," and Niacin (Vitamin B3), the "bioactive agent." According to the contentions, "Niacin will readily `bind' and/or `coordinate' with the catechin multimers of the green tea extract, and assemble into complexes as claimed." (Ocean Spray Exh. D at 2:28-3:4).
Trivitis asserts that "each element of the asserted claims is present" in the Cranergy drink. Alternatively, if any element is not "found to be literally present in [Cranergy] it is present under the doctrine of equivalents." (
A motion for summary judgment shall be granted where "there is no genuine issue as to any material fact and . . . the moving party is entitled to judgment as a matter of law." FED. R. CIV. P. 56(c);
The court must examine the evidence in the light most favorable to the non-moving party.
Determination of patent infringement is a two-step procedure. "First, the claim must be properly construed to determine its scope and meaning. Second, the claim as properly construed must be compared to the accused device or process."
The primary evidence submitted by Trivitis in support of its motion for summary judgment, and in opposition to Ocean Spray's motion, consists of the declarations and testimony of Drake Larson, the CEO of Trivitis, and Dale Shellhamer, Ph.D. Ocean Spray contends that Mr. Larson's testimony must be excluded because (1) he lacks the training or knowledge needed to qualify him as an expert and (2) it is not based on reliable testing within the meaning F.R.E. 702. Ocean Spray also seeks to exclude the testimony of Mr. Shellhamer because (1) it relies entirely upon the flawed and unreliable data produced by Mr. Larson and (2) his two page report is entirely conclusory.
Pursuant to the recently revised Federal Rule of Evidence 702,
(b) the testimony is based on sufficient facts or data;
(c) the testimony is the product of reliable principles and methods; and
Before admitting expert testimony, the trial court must conduct "a preliminary assessment of whether the reasoning or methodology underlying the testimony is scientifically valid and of whether that reasoning or methodology properly can be applied to the facts in issue."
The Supreme Court has set forth several factors that a district court should consider in determining admissibility of expert testimony. Those factors are (1) testing, (2) peer review and publication, (3) general acceptance in the scientific community, and (4) the known or potential rate of error.
The first issue raised is whether Mr. Larson is qualified to provide expert testimony in the area of high pressure liquid chromatography ("HPLC") and mass spectrometry analysis. The second issue is whether the methodologies applied by Mr. Larson satisfy the threshold requirements for admissibility.
By way of background, chromatography "is the collective term for a set of laboratory techniques for the separation of mixtures." http:wikipedia.org/wiki/chromatographic; (Ct. Dkt. 38, Exh. F, Larson Report). HPLC "is a chromatographic technique used to separate a mixture or compounds in analytical chemistry and biochemistry with the purpose of identifying, quantifying and purifying the individual components of the mixture." http:wikipedia.org/wiki/high-performance_liquid_chromatography. The term "mass spectrometry" is a term referring to an "analytical technique that measures the mass-to-charge ratio of charged particles. It is used for determining masses of particles, for determining the elemental composition of a sample or molecule, and fore lucidating the chemical structures of molecules." http:wikipedika.org/wiki/Mass_spectometry.
The relevant record on Mr. Larson's qualifications as an expert in the fields of HPLC and mass spectrometry is virtually non-existent. Mr. Larson, the Patent holder and CEO of Trivitis, graduated from UCLA in 1976 with a degree in mathematics. He does not have a degree in chemistry and testified that his only formal chemistry education was a high school chemistry class and college chemistry courses. (Ct. Dkt. 38, Exh. E at 70:19-20; Ct. Dkt. 31, Exh. E at 66:20-70:11). Mr. Larson's post-college education is limited to week-long courses dealing with the FDA and seminars relating to "product labeling, and making claims." (Ct. Dkt. 43 ¶5).
In opposition to the motion to exclude, Trivitis argues Mr. Larson, through experience and training, "has developed the requisite skill to testify as an expert on the chemistry issue present in this case. Mr. Larson's Small Business Innovation Research Program grant applications document very specific research study and analysis of the chemistry issues involved in this case. Mr. Larson has been researching, studying, and experimenting in the field of art for more than eleven or twelve years." (Oppo. at p.3: 13-18). Trivitis represents that Mr. Larson obtained experience through "studying and experimenting in the field of wine chemistry and amidating various favones for more than fifteen years." (Oppo. at p.2:14-15). The difficulty with these arguments is that Trivitis provides no evidence to support the conclusory statement that Mr. Larson has "experience and training" in HPLC or mass spectrometry.
Based upon the present evidentiary record, Trivitis fails to meet its threshold showing that Mr. Larson is qualified as an expert to provide testimony on HPLC or mass spectrometry. Consequently, the court does not consider this testimony upon ruling on the motions for summary judgment.
Admissibility of expert scientific testimony must satisfy two threshold showings. First, the court "must determine nothing less than whether the experts' testimony reflects `scientific knowledge,' whether their findings are `derived by the scientific method,' and whether their work product amounts to `good science.'"
While the admissibility analysis on matters of scientific research presents the court with a "daunting" task,
Ocean Spray challenges the methodology used by Mr. Larson in connection with his HPLC analysis. Mr. Larson relied upon light scattering ("LS") detection instead of ultraviolet ("UV") detection. Ocean Spray identifies its own expert as well as patent prosecutions that involved UV detection in HPLC experiments involving catechins or catechin multimers. (Exhs. G, H, I, J). While the experiments conducted by Mr. Larson used both light scattering techniques, he based his opinions only on the unconventional LS data.
Trivitis contends that Mr. Larson has many years of research experience "with the chemistry involved in the field of art . . . [and has] conducted experiments of Ocean Spray's product using established, pre-litigation, methodologies and research." (Oppo at p.5:12-16). The difficulty with this conclusory statement is that Trivitis fails to cite any part of the record to substantiate this conclusion. The court also notes that Trivitis repeatedly makes conclusory statements without citation to the record (i.e. "Mr. Larson discovered that LS detection is an appropriate form of detection"; "testing was conducted in a scientifically acceptable manner"; and "spectrometry analysis has been used for over decades and is a good indicator regarding a sample's purity," Oppo. at p. 6:5-28). Without specific citation to an evidentiary basis for these statements, Trivitis simply fails to carry its burden.
Trivitis also contends that HPLC and mass spectrometry are scientifically tested and accepted methodologies. (Oppo. at p.4:26-28). This argument misses the mark. As noted by Ocean Spray, the issue is whether Mr. Larson used accepted methods when he designed the HPLC and mass spectrometry experiments, prepared the test samples, and analyzed the resulting data. On this issue, Trivitis fails to meet its evidentiary burden.
Trivitis also argues that the affidavits attached to the declaration of Mr. Larson constitute sufficient peer review to validate the employed methodologies. The court has located the majority of the affidavits referenced in the Larson Declaration and concludes that Trivitis fails to establish objective verifiable evidence that the testimony is based on scientifically valid principles.
In sum, the court concludes that Trivitis (1) fails to establish that Mr. Larson is a qualified expert and (2) fails to come forward with sufficient evidence to show that the methodologies and principles applied by Mr. Larson are based on scientifically valid principles. Consequently, the Larson Declaration and the Dale Shellhamer Declaration (who relies upon the Larson Declaration in reaching his opinions), are not admissible.
Applying the properly constructed claims to Cranergy, Ocean Spray concludes that it did not infringe the Patent. First, Ocean Spray asserts that the alleged infringing substance in Cranergy, epigallocatechin gallate, does not meet the Patent's definition of "catechin" or "multimer." In essence, Professor Mitchell explains that the structural formula of epigallocatechin gallate is not a catechin multimer because it "does not contain any copy of catechin, as defined by the Court's construction, and certainly does not contain two copies of catechin." (Exh. E, Mitchell report at 11-12). He concludes from this analysis that "epigallocatechin gallate as that molecule exists in green tea is not a catechin molecule as catechin molecules are defined by the Court. . . [and] there is nothing to suggest [] that there exists two copies of catechin" such that it is a "catechin multimer" within the meaning of Plaintiff's Claims 10 and 11.
Based upon Ocean Spray's evidentiary showing, the burden shifts to Trivitis to show there is a genuine issue of material fact the allegedly infringing substance in green tea is, as claimed, a "catechin multimer" within the meaning of the Patent. The entirety of the opposition consists of the following statement:
(Oppo at p. 5:4-9). The court concludes that this statement fails to raise a genuine issue of material fact. The statement does not cite to the evidentiary record or provide the court with any guidance to locate the evidentiary support for this conclusory statement. As noted earlier, it is not the role of the court to mine the evidentiary record to support a party's arguments.
Second, Ocean Spray asserts that Cranergy does not contain a bioactive agent "complexed" with a catechin multimer, a prerequisite for Plaintiff's claims. The infringing contention alleges that Cranergy contains niacin as the "bioactive agent" which forms a complex with epigallocatechin gallate, the alleged catechin multimer. Professor Mitchell supervised a series of experiments to evaluate the ability of epigallocatechin gallate and similar compounds to form stable complexes with niacin in a solution of pH 3 (equivalent to the pH of Cranergy). Professor Mitchell concluded that the "chemistry of [these compounds] suggest that [they] would only have fleeting interactions in solutions" not detectable by her experiments and therefore not sufficient for delivery of niacin to the target sites. (Exh. E at 12-13, 25). From this evidentiary showing the court concludes, subject to an evidentiary challenge by Trivitis, that Cranergy does not violate the Patent.
Based upon this evidentiary showing, the burden shifts to Trivitis to show there is a genuine issue of material fact that the allegedly infringing product contains a "bioactive agent" "complexed with" a "catechin multimer." The entirety of the opposition consists of the statement: "Per,
In sum, the court grants summary judgment in favor of Defendant Ocean Spray and against Plaintiff Trivitis on the infringement claims alleged in Plaintiff's complaint. The Clerk of Court is instructed to close the file.
(Motion at p.10:4-8). Without citation to the evidentiary record, the court is unable to assess the evidentiary value of an unsupported factual assertion.